BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Trump Buys SpaceX Shares After Record IPO 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
SK Hynix Shares Fall as Workers Reject Wage Deal 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Add as a preferred source on Google
BRIDGEWATER, N.J., April 25, 2018 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its first quarter 2018 financial results on Wednesday, May 2, 2018.
Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Wednesday, May 2, 2018 to discuss the financial results and provide a business update.
Shareholders and other interested parties may participate in the conference call by dialing (844) 707-0669 (domestic) or (703) 639-1223 (international) and referencing conference ID number 4567628. The call will also be webcast live on the internet on the company's website at www.insmed.com.
A replay of the conference call will be accessible approximately two hours after its completion through May 9, 2018 by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international) and referencing conference ID number 4567628. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical Company focused on the unmet needs of patients with rare diseases. The Company's lead product candidate is ALIS, which is in late-state development for adult patients with treatment refractory NTM lung disease caused by MAC, which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.
Contact:
Blaine Davis
Insmed Incorporated
(908) 947-2841
[email protected]
